{"entity":{"id":"nct05355298","kind":"trial","name":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of AMP945 ascending doses in pancreatic ductal adenocarcinoma, run by Amplia Therapeutics Limited, active and no longer recruiting.","summary":"ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05355298 by Amplia Therapeutics Limited, with 62 participants enrolled, started 2022-05-31 and due to reach its primary completion in 2027-02-01. Interventions recorded: AMP945 ascending doses and AMP945 RP2D.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05355298","url":"https://clinicaltrials.gov/study/NCT05355298"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05355298","phase":"1/2","setting":"A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients","sponsor":"Amplia Therapeutics Limited","enrolled":62,"outcomes":[]},"route":"/trials/nct05355298/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}]}}